一、药品基本情况 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，三生国健药业（上海）股份有限公司（以下简称"公司"）收到国家药品监督管理局核准签发的 《受理通知书》，公司产品重组抗IL-4Rα人源化单克隆抗体注射液（研发代码：SSGJ-611）的新药上市 申请（NDA）获得受理。 由于药品在获得上市申请受理后，尚需通过国家药品监督管理局相关审评程序并获批准后方可上市、销 售。本次新药上市申请能否获得批准存在不确定性。敬请广大投资者谨慎决策，注意防范投资风险。 现将相关情况公告如下： 三、风险提示 根据我国药品注册相关的法律法规要求，药品在获得上市申请受理后，尚需通过国家药品监督管理局相 关审评程序并获批准后方可上市、销售。本次新药上市申请能否获得批准存在不确定性。 由于医药产品具有高科技、高风险、高附加值的特点，药品从临床试验报批到投产周期长、环节多，容 易受到一些不确定性因素的影响，公司将按有关规定积极推进上述研发项目，并严格按照有关规定及时 对项 ...

Core Insights - Nektar Therapeutics' stock surged 51% following positive Phase II trial results for its lead asset, rezpeg, in treating atopic dermatitis (AD) [1][6] Group 1: Trial Results - In the REZOLVE-AD study, a 24 µg/kg dose of rezpeg maintained disease control across four measures of AD severity at the one-year mark [2] - Among patients on a monthly dosing regimen who achieved EASI-50 during the 16-week induction, 71% and 80% achieved EASI-75 and EASI-90, respectively, after one year [3] - For quarterly-dosed patients meeting the same induction criteria, 83% and 78% achieved EASI-75 and EASI-90 at the one-year point [3] - Total AD clearance (EASI-100) was achieved by 22% of monthly dose patients and 18% of quarterly dose patients at week 52 [3] Group 2: Patient Outcomes - Rezpeg led to 85% and 63% of patients achieving vIGA-AD scores of 0 or 1 across monthly and quarterly dosing schedules at 52 weeks [4] - Improvement in itch NRS scores was observed in 75% of monthly and 77% of quarterly dosing patients [4] - During the maintenance period, 33% of previous non-responders in the monthly cohort achieved EASI-90, while 26% of the quarterly cohort experienced the same outcome [4] Group 3: Safety Profile - Rezpeg was found to be safe and tolerable, with the most common treatment-emergent adverse event being mild injection site reactions [5] - No serious adverse events such as conjunctivitis, oral ulcers, cardiovascular issues, or malignancies were reported [5] Group 4: Market Reaction - Following the Phase II results, Nektar's stock price increased from $37.07 to $56.00, reflecting investor confidence [6] - The stock may have also benefited from the announcement of a $3 million underwritten public offering of common stock [6] - Previous positive outcomes in the REZOLVE-AD study had already led to a significant stock increase of over 150% when data was presented at the EADV Congress in September 2025 [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Insights - The approval of Lurcatinib cream marks a significant opportunity in the vitiligo market, being the first and only targeted therapy approved in China for this condition [7] - Clinical trials have shown positive results, with a significant percentage of patients achieving at least a 75% improvement in facial vitiligo area score after 24 weeks of treatment [7] - The company is also pursuing additional indications for Lurcatinib cream, including atopic dermatitis, which could further enhance its market potential [7] Financial Forecast and Valuation - Revenue projections for the company are as follows: 2023: 8,013 million RMB, 2024: 7,469 million RMB, 2025: 8,166 million RMB, 2026: 9,628 million RMB, and 2027: 12,069 million RMB, with growth rates of -12.4%, -6.8%, 9.3%, 17.9%, and 25.4% respectively [6] - Net profit forecasts are: 2023: 2,401 million RMB, 2024: 1,620 million RMB, 2025: 1,681 million RMB, 2026: 1,942 million RMB, and 2027: 2,333 million RMB, with growth rates of -26.3%, -32.5%, 3.8%, 15.6%, and 20.1% respectively [6] - The estimated reasonable market value for the company in 2026 is 677 billion HKD, based on a combination of price-to-earnings and price-to-sales ratios [7]

Core Viewpoint - Guangdong Heng Rui Medicine Co., Ltd. has initiated a clinical trial to evaluate the bioavailability and safety of SHR-1819 injection using different injection devices, with the trial registered under CTR20254700 and first disclosed on November 27, 2025 [1] Group 1: Clinical Trial Details - The clinical trial is a randomized, parallel, open study involving healthy subjects [1] - The trial aims to compare the bioavailability of SHR-1819 injection using pre-filled safety injection needles (PFS) and pre-filled automatic injection pens (AI) [1] - The primary endpoint includes comparing pharmacokinetic parameters Cmax and AUClast of SHR-1819 injection with different devices [1] Group 2: Drug Information - SHR-1819 injection is a biological product indicated for atopic dermatitis, a chronic, recurrent inflammatory skin disease characterized by itching, erythema, and papules [1] - Secondary endpoints include assessing the safety of SHR-1819 (vital signs, physical examination) and the positive occurrence rate and timing of anti-drug antibodies (ADA) [1] Group 3: Trial Status - The current status of the trial is ongoing (not yet recruiting) with a target enrollment of 160 participants [2]

Core Viewpoint - The article discusses the challenges and advancements in the treatment of atopic dermatitis (AD), highlighting the issues of steroid misuse and the introduction of a new non-steroidal innovative drug that aims to break the cycle of treatment and relapse [3][4][5]. Group 1: Atopic Dermatitis Overview - Atopic dermatitis is a chronic, recurrent inflammatory skin disease often associated with other allergic conditions, with a rising incidence globally, particularly severe in China where the prevalence in children aged 1-7 years is 12.94% and in infants aged 1-12 months is 30.48% [4]. - The misuse of steroid creams has become a significant issue, leading to severe side effects such as irreversible skin changes and dependency, as patients often self-medicate without proper guidance [3][5]. Group 2: Treatment Challenges - The current treatment landscape is characterized by a dichotomy of steroid overuse and fear of steroid use, complicating effective management of the disease [6]. - Traditional treatments involve a trade-off between the rapid relief provided by steroids and the long-term damage they can cause to the skin, while non-steroidal options are perceived as slower and less effective [6]. Group 3: Innovative Solutions - The introduction of the innovative drug, Zeli Mei® (bimekizumab), represents a significant advancement, being the first aromatic hydrocarbon receptor (AhR) modulator approved for treating AD in patients over 2 years old [8]. - Clinical trials have shown promising results, with nearly 60% of patients achieving deep itch relief after 8 weeks of treatment, and 70% of patients remaining relapse-free for 10 months after stopping the medication [8]. - The Chinese market for eczema topical agents is projected to reach approximately 5.28 billion yuan in 2024, with steroid-based medications currently dominating the market, exemplified by "Pian Yan Ping" achieving sales of 1.04 billion yuan in 2023 [8].

Core Insights - The article discusses the challenges of managing atopic dermatitis (AD) in China, highlighting the issues of hormone abuse and the need for innovative treatments [1][2][3] - A new non-steroidal drug, Zeli Mei® (bimekizumab), has been approved for the treatment of AD, offering a potential solution to the ongoing cycle of flare-ups and treatment failures [2][3] Regulatory and Market Context - The current regulatory gray area and excessive marketing contribute to the widespread abuse of steroid medications for AD [2] - The prevalence of AD is increasing, with a reported incidence of 12.94% among children aged 1-7 years and 30.48% among infants aged 1-12 months in China [1] Treatment Challenges - Patients often resort to self-medication due to the availability of various topical treatments, leading to a dual challenge of overuse and fear of necessary steroid treatments [2] - Traditional steroid treatments are effective but can cause long-term skin damage, while non-steroidal options are safer but take longer to show results [2] Innovative Solutions - The introduction of Zeli Mei® represents a significant advancement, being the first aromatic hydrocarbon receptor (AhR) modulator approved for AD treatment in children over 2 years old and adults [3] - Clinical trials indicate that nearly 60% of patients experienced significant itch relief after 8 weeks of treatment, and 70% of patients remained relapse-free for 10 months after stopping the medication [3] Market Potential - China has approximately 70 million AD patients, with over 90% requiring topical treatments, indicating a substantial market opportunity for new therapies [3] - The market for eczema topical agents in China is projected to reach approximately 5.28 billion yuan in 2024, with steroid medications currently holding a significant market share [3]

Summary of Apogee Therapeutics Conference Call Company Overview - **Company**: Apogee Therapeutics (NasdaqGM:APGE) - **Date**: November 13, 2025 - **Key Speakers**: Michael Henderson (CEO), Carl Dambkowski (CMO), Jeff Hartness (CCO), Jane Pritchett Henderson (CFO) Key Industry and Company Insights Asthma Data and APG777 - **APG777 Phase 1 Readout**: Expected in Q1 2026, focusing on asthma data [2][4] - **Comparison with Ebglyss**: Ebglyss failed due to underdosing (20% of effective dose) and lack of targeting type 2 disease [2][3] - **Targeting Type 2 Disease**: Apogee aims to enroll high FeNO patients, expecting a change in FeNO similar to Dupixent (15-20 parts per billion) [3][4] - **Loading Dose**: APG777 will use a loading dose of 720 mg, compared to Ebglyss's 500 mg [5][7] Future Plans in Asthma - **Expansion Plans**: If successful, Apogee plans to initiate Phase 2B studies in asthma and EoE, contingent on atopic dermatitis data [8][9] - **Overlap with Atopic Dermatitis**: Approximately 30% overlap between atopic dermatitis and asthma patients [9] Atopic Dermatitis Phase 2 Program - **Part A Results**: Positive results reported, with 52-week maintenance data expected in Q1 2026 [10][11] - **Success Metrics**: Aiming for maintenance of EC75 response at week 52, with a benchmark of 72% for Dupixent [11][12] - **Dosing Strategy**: Plans for every three-month and six-month dosing regimens, with data expected to inform Phase 3 studies [12][13] Mechanistic Insights - **Differentiation from Competitors**: APG777 targets IL-13 and IL-4 receptors, potentially leading to better durability of response compared to competitors [16][17] Part B Study Design - **Dose Optimization**: Part B will explore three doses versus placebo, aiming to fully understand the dose-response curve [19][20] - **Market Research**: Positive feedback from physicians, with 60% preferring APG777 over competitors [37][38] Market Positioning - **Market Disruption Potential**: Ebglyss and Nemluvio are currently strong competitors, but Apogee believes it can capture significant market share [38][39] - **Combination Therapy**: Plans to explore combinations with APG990, aiming for additive efficacy [32][33] Financial Position - **Cash Reserves**: Apogee has $913 million in cash, providing a runway into the second half of 2028 [30] Timeline for Future Trials - **Phase 3 Trials**: Expected to start next year, with a potential market launch in 2029 [27] Additional Insights - **Conjunctivitis Rates**: Lower rates observed in higher exposure groups, aligning with Dupixent's data [26] - **Combination with TSLP**: Future plans to explore combinations with TSLP based on upcoming data [41][44] Conclusion Apogee Therapeutics is positioned to make significant advancements in the treatment of asthma and atopic dermatitis with its APG777 product. The company is focused on differentiating its therapies through targeted dosing and mechanistic advantages, while also preparing for future market competition and expansion into additional indications.

Summary of Apogee Therapeutics Conference Call Company Overview - **Company**: Apogee Therapeutics (NasdaqGM:APGE) - **Focus**: Development of potentially best-in-class antibodies for atopic dermatitis and asthma, with a busy pipeline ahead [1][2] Key Points on Atopic Dermatitis - **Market Potential**: The atopic dermatitis market is large, with Dupixent continuing to grow despite new entrants like Ebglyss and Nemluvio, which are annualizing at approximately $650 million and $500 million respectively [3][4] - **Biologic Penetration**: Current biologic penetration in the atopic dermatitis space is around 10%, indicating significant growth potential [4] - **Triple 7 and Combination Approach**: Apogee aims to position its drug, Triple 7, and its combination approach (279) as frontline treatments for atopic dermatitis, with phase three trials expected to start by the end of next year [2][6] Clinical Data Highlights - **Phase 2 Trial Results**: The phase 2 trial showed promising results with a placebo-adjusted EASI-75 of 42.5%, indicating strong efficacy compared to existing treatments [7][8] - **Rapid Itch Relief**: Significant itch relief was observed as early as 48 hours post-treatment, comparable to Nemluvio [8][10] - **Safety Profile**: Conjunctivitis rates were similar to those seen with Dupixent, but no discontinuations due to this side effect were reported [11][12] Future Developments - **Upcoming Data**: Maintenance data for dosing every three and six months is expected in Q1 of next year, which will be crucial for regulatory discussions [14][15] - **Combination Studies**: A study combining Triple 7 with OX40 ligands (279) is currently enrolling, aiming to replicate JAK-like efficacy without associated safety issues [22][24] Asthma Pipeline - **Asthma Focus**: Apogee is prioritizing asthma due to the overlap with atopic dermatitis patients, with proof of concept studies expected in Q1 [28][30] - **Dosing Strategy**: A single dose of 720 mg is planned to evaluate efficacy against Dupixent, particularly in reducing FeNO levels [29][30] Financial Position - **Cash Reserves**: Apogee has over $900 million in cash, providing a runway into the second half of 2028, covering phase three top-line data [33] Conclusion - Apogee Therapeutics is positioned to make significant strides in the atopic dermatitis and asthma markets with a robust pipeline and promising clinical data. The company is focused on establishing its products as frontline therapies while maintaining a strong financial position to support ongoing and future clinical trials.

Core Insights - The "Expert Consensus on the Treatment and Management of Atopic Dermatitis (2025 Edition)" has been published, providing standardized clinical application guidance for the innovative drug, Zeli Mei Ben Wei Mo De Ointment [1][2] - Atopic dermatitis (AD) has a prevalence rate of 10%-15% among children in China, making it the leading non-fatal skin disease burden [1] - The consensus emphasizes the importance of Zeli Mei Ben Wei Mo De Ointment as a treatment option for the two-thirds of patients with mild to moderate AD, based on research data from the Chinese population [1][2] Treatment Mechanism - Zeli Mei Ben Wei Mo De Ointment works by inhibiting type 2 inflammatory cytokines and repairing the skin barrier, specifically targeting IL-4/IL-13 induced tight junction damage [2] - Clinical trials indicate that the ointment can reduce and eliminate skin lesions while alleviating itching, with most adverse reactions being mild to moderate [2] Treatment Guidelines - The consensus provides clear guidelines for treating special areas and populations, recommending the use of moderately potent topical medications in sensitive areas to avoid the risk of skin atrophy from long-term corticosteroid use [2] - The dual mechanism of Zeli Mei Ben Wei Mo De Ointment offers unique advantages in addressing the inflammatory responses and barrier defects commonly seen in AD patients in China, particularly for children and those contraindicated for steroids [2] - The publication of the consensus aims to guide medical institutions in standardizing the selection of topical medications for AD, promoting the standardization of AD diagnosis and treatment in China [2]

Core Viewpoint - Company subsidiary Guangdong Hengrui Medicine Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of SHR-1905 injection, targeting atopic dermatitis [1] Group 1: Clinical Trial Approval - The clinical trial application for SHR-1905 injection was accepted on July 17, 2025, and meets the requirements for drug registration [1] - The approval allows the company to conduct clinical trials for atopic dermatitis [1] Group 2: Product Information - SHR-1905 injection is a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), which can block the release of inflammatory cytokines and inhibit downstream inflammatory signaling [1] - The product aims to improve inflammatory conditions and control disease progression [1] Group 3: Market Context - A similar product, Tezepelumab (AstraZeneca/Amgen, marketed as Tezspire), has been approved and is projected to generate global sales of approximately $1.22 billion in 2024 [1] - The cumulative R&D investment for SHR-1905 injection has reached approximately 209.62 million yuan [1]